ArticlePloS one2014
Dopamine reduction in the substantia nigra of Parkinson's disease patients confirmed by in vivo magnetic resonance spectroscopic imaging.
Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 2 syntheses or guidelines pooled it, 102 citations in OpenAlex.
- Speech, voice, and language outcomes following deep brain stimulation: A systematic review.PloS one · 2024Pooled it
- Health Benefits of Endurance Training: Implications of the Brain-Derived Neurotrophic Factor-A Systematic Review.Neural plasticity · 2019Pooled it
- Neurometabolic Signatures of Alexithymia and Visuospatial Abilities in Parkinson's Disease: An ExploratoryJournal of clinical medicine · 2026Article
- Reimagining biogenic amine signaling in the brain and beyond.Trends in neurosciences · 2026Review
- Article
- Exploring the Impact of Dopaminergic Treatment on Creative Expression in Parkinson's Disease: A Scoping Review.Journal of clinical medicine · 2025Review
- Dopamine stabilized in ultra-nanoreservoirs for controlled delivery in parkinson's disease.Nanomedicine (London, England) · 2025Article
- Hippocampal γCaMKII dopaminylation promotes synaptic-to-nuclear signaling and memory formation.bioRxiv : the preprint server for biology · 2024Article
- Exploring the Association between Cathepsin B and Parkinson's Disease.Brain sciences · 2024Article
- Machine learning nominates the inositol pathway and novel genes in Parkinson's disease.Brain : a journal of neurology · 2024Article
- Effectiveness of Continuous Dopaminergic Therapies in Parkinson's Disease: A Review of L-DOPA Pharmacokinetics/Pharmacodynamics.Journal of Parkinson's disease · 2024Review
- Glutathione Depletion and Concomitant Elevation of Susceptibility in Patients with Parkinson's Disease: State-of-the-Art MR Spectroscopy and Neuropsychological Study.ACS chemical neuroscience · 2023Article
- Emerging Role of Plant-Based Bioactive Compounds as Therapeutics in Parkinson's Disease.Molecules (Basel, Switzerland) · 2023Review
- Comparative study of bilateral putamen for patients with severe Parkinson's disease detected byQuantitative imaging in medicine and surgery · 2023Article
- Model-based optimization of controlled release formulation of levodopa for Parkinson's disease.Scientific reports · 2023Article
- Article
- Automatic and controlled attentional orienting toward emotional faces in patients with Parkinson's disease.Cognitive, affective & behavioral neuroscience · 2023Article
- T-type calcium channels as therapeutic targets in essential tremor and Parkinson's disease.Annals of clinical and translational neurology · 2023Review
- Metabolomic Footprint of Disrupted Energetics and Amino Acid Metabolism in Neurodegenerative Diseases: Perspectives for Early Diagnosis and Monitoring of Therapy.Metabolites · 2023Review
- Molecular Imaging of the GABAergic System in Parkinson's Disease and Atypical Parkinsonisms.Current neurology and neuroscience reports · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesMetabolic changes in the substantia nigra of patients with Parkinson's disease were previously investigated in different molecular-pathological examinations. The aim of our study was the in vivo measurement of these alterations using three-dimensional magnetic resonance spectroscopic imaging.
methods21 patients with Parkinson's disease and 24 controls were examined using magnetic resonance spectroscopic imaging at 3 Tesla. The spectra of rostral and caudal substantia nigra regions were analyzed using LCModel. For spectral fitting, an adjusted basis data set with pathology-specific metabolites and macromolecules was used to better reproduce the in vivo spectra. To assess differences between both groups more accurately, especially in metabolites at lower concentrations, group-averaged spectra were evaluated in addition to the analysis of individual data.
resultsWe found significantly decreased N-acetylaspartate, choline, creatine, myo-inositol, glutathione and dopamine concentrations in patients with Parkinson's disease compared to controls, whereas glutamine+glutamate, γ-aminobutyric acid, and homovanillic acid were slightly increased. According to anatomical features, clear differences in the biochemical profiles were found between rostral and caudal substantia nigra voxels in both groups.
conclusionsReduced N-acetylaspartate and dopamine concentrations result from progressive degeneration of dopamine-producing neurons within the substantia nigra pars compacta. Decreased creatine levels can be interpreted as impaired energy metabolism due to mitochondrial dysfunction. Lower glutathione concentrations might be a cause or consequence of oxidative stress. Furthermore, slightly increased glutamine+glutamate and γ-aminobutyric acid levels are expected based on post mortem data in Parkinson's disease. To the best of our knowledge, this is the first non-invasive confirmation of these metabolic changes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.